IFF Slashes 2026 Revenue Outlook by $3B, Q2 Misses Across the Board
IFF sits 37% above its 52-week low of $59.14.
Summary
IFF cut its full-year 2026 revenue guidance to $7.4B-$7.6B, down sharply from the prior $10.5B-$10.8B range, and lowered adjusted operating profit forecast to $1.53B-$1.60B from $2.05B-$2.15B. The revision reflects weak demand driven by inflation, shifting consumer habits, and GLP-1 drug adoption. Q2 sales of $1.95B missed the $2.69B consensus, and adjusted EPS of $0.82 fell well short of the $1.12 estimate. This follows the May sale of the food ingredients business for $4.3B, which partially explains the top-line reset but the magnitude of the miss and guidance cut signals deeper demand erosion. The stock, trading near its 52-week high, faces a sharp repricing as the market digests the severity of the downgrade.
At the time of this announcement, IFF was trading at $81.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $20.7B. The 52-week trading range was $59.14 to $84.45. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.